Ryder System, Inc. (NYSE:R ) Q3 2024 Earnings Conference Call October 24, 2024 11:00 AM ET Company Participants Calene Candela – Vice President, Investor Relations Robert Sanchez – Chairman and Chief Executive Officer John Diez – Executive Vice President and Chief Financial Officer Tom Havens – President, Fleet Management Solutions Steve Sensing – President, Supply Chain Solutions and Dedicated Transportation Solutions Conference Call Participants Jordan Alliger – Goldman Sachs Christyne McGarvey – Morgan Stanley Jeff Kauffman – Vertical Research Partners Scott Group – Wolfe Research Brian Ossenbeck – JPMorgan Daniel Imbro – Stephens Operator Good morning, and welcome to the Ryder System Third Quarter 2024 Earnings Release Conference Call. All lines are in a listen-only mode until after the presentation.
The headline numbers for Ryder (R) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ryder (R) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.39 per share. This compares to earnings of $3.58 per share a year ago.
TAMPA, FL / ACCESSWIRE / October 23, 2024 / Due to recent storms that have devastated the Southeastern United States, Atlantic Power & Infrastructure Corp. (OTC PINK:AWSL) is experiencing a surge of interest in the incredible uses of Flexi®-Pave to mitigate stormwater management. According to Ryan Maue, the former Chief Scientist for the North Oceanic Atmospheric Administration, Hurricane Helene dumped approximately 40 trillion gallons of water in her path, stunning experts and leaving local communities in ruin in the aftermath that followed.
Ryder (R) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Besides Wall Street's top -and-bottom-line estimates for Ryder (R), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
R's third-quarter 2024 revenues are expected to have benefited from strength across all segments.
Further Solidifies International Patent Portfolio and Underscores the Company's Commitment to Innovation of SI Joint Stabilization Systems and Methods LOS GATOS, CA / ACCESSWIRE / October 17, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the issuance of U.S. Patent Nos. 12,115,075, 12,115,076 and 12,115,077.
Ryder (R) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLEVELAND, OH / ACCESSWIRE / October 16, 2024 / Mace Security International, Inc. (OTCQB:MACE) ("Mace") today, following an extensive strategic alternatives process, announced that Mace and W Electric Intermediate Holdings, LLC have entered into a definitive Agreement and Plan of Merger ("Merger Agreement") for a business combination that will result in Mace becoming a wholly-owned subsidiary of W Electric Intermediate Holdings, LLC. Headquartered in Pittsburgh, Pennsylvania, W Electric Intermediate Holdings, LLC is the parent company of a global brand operator and value-added distributor of consumer and industrial products.
R stock appreciates more than 30% in the past 6 months on multiple tailwinds.
Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada DENVER, CO / ACCESSWIRE / October 1, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, and Lupin Pharma Canada Ltd ("Lupin"), a subsidiary of global pharma major Lupin Limited, today announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu's Adzenys XR-ODT® and Cotempla XR-ODT® product lines in Canada. Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder ("ADHD") in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®.